JumpStart Ventures Invests $250,000 in Thermalin Diabetes Inc.
03/29/2010
"Over the next 20 years, worldwide insulin sales are expected to grow from $12 billion to $54 billion, JumpStart Ventures partner Ted Frank told Crain's Cleveland Business. "That growth, combined with the medical community's interest in insulin with higher performance, fewer side effects, and storage flexibility, position Thermalin's pipeline to be in high demand."
Thermalin will use the funds to validate its insulin analogs' characteristics, locate a manufacturer, and proceed in the investigational drug process with the FDA.
The company's products include a faster meal-time insulin that is expected to reduce long-term side effects. The insulin can also be stored at higher temperatures, which would make transport and delivery easier.
Project Announcements
Pulmuone Foods USA Expands Ayer, Massachusetts, Production Operations
04/13/2026
HF Rubber Expands Topeka, Kansas, Production Operations
04/12/2026
Google Plans Putnam County, West Virginia, Data Center Operations
04/12/2026
Stanley Black & Decker Expands Mission, Texas, Production Operations
04/12/2026
Vertiv Expands Westerville-Ironton, Ohio, Operations
04/12/2026
Blue Sky Innovators Expands Fairfax County, Virginia, Operations
04/12/2026
Most Read
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
Last Word: Don’t Lose by Winning
Q1 2026
-
Advanced Manufacturing Isn’t a Buzzword—It’s a Different Location Strategy
Q1 2026
-
40th Annual Corporate and 22nd Annual Consultant Site Selection Survey Results
Q1 2026